GBT Announces Participation in Upcoming Investor Conferences
November 12 2021 - 8:00AM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today
announced that it will participate in a virtual fireside chat at
the Stifel 2021 Virtual Healthcare Conference on Wednesday,
November 17, 2021, at 2:00 p.m. ET. The company will also
participate at the Piper Sandler 33rd Annual Virtual Healthcare
Conference, with the fireside chat available on Monday, November
22, 2021, at 10:00 a.m. ET.
The fireside chats will be available on GBT’s website
at www.gbt.com in the Investors section. Replays will be
archived and available for one month following each event.
About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical
company dedicated to the discovery, development, and delivery of
life-changing treatments that provide hope to underserved patient
communities. Founded in 2011, GBT is delivering on its goal to
transform the treatment and care of sickle cell disease (SCD), a
lifelong, devastating inherited blood disorder. The company has
introduced Oxbryta® (voxelotor) tablets, the first
FDA-approved treatment that directly inhibits sickle hemoglobin
polymerization, the root cause of red blood cell sickling in SCD.
GBT is also advancing its pipeline program in SCD with inclacumab,
a P-selectin inhibitor in Phase 3 development to address pain
crises associated with the disease, and GBT021601 (GBT601), the
company’s next generation hemoglobin S polymerization inhibitor. In
addition, GBT’s drug discovery teams are working on new targets to
develop the next wave of potential treatments for SCD. To learn
more, please visit www.gbt.com and follow the company on
Twitter @GBT_news.
Contact:Steven Immergut
(media)650-410-3258simmergut@gbt.com
Courtney
Roberts (investors)650-351-7881croberts@gbt.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Apr 2023 to Apr 2024